Compounds > hydroxynefazodone
Page last updated: 2024-11-12

hydroxynefazodone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

hydroxynefazodone: an active metabolite of the antidepressant nefazodone; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11755137
CHEBI ID186525
SCHEMBL ID5694527
MeSH IDM0243729

Synonyms (13)

Synonym
hydroxynefazodone
98159-83-2
FT-0669888
98159-82-1
CHEBI:186525
2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-5-(1-hydroxyethyl)-4-(2-phenoxyethyl)-1,2,4-triazol-3-one
3h-1,2,4-triazol-3-one, 2-(3-(4-(3-chlorophenyl)-1-piperazinyl)propyl)-2,4-dihydro-5-(1-hydroxyethyl)-4-(2-phenoxyethyl)-
2-(3-(4-(3-chlorophenyl)-1-piperazinyl)propyl)-2,4-dihydro-5-(1-hydroxyethyl)-4-(2-phenoxyethyl)-3h-1,2,4-triazol-3-one
unii-325402pvuu
325402pvuu ,
SCHEMBL5694527
DTXSID60913420
Q27256142

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Safety and tolerance assessment involved analyses of adverse events, laboratory tests, vital signs, ophthalmic examinations, and ECGs."( Safety, tolerance, and preliminary pharmacokinetics of nefazodone after administration of single and multiple oral doses to healthy adult male volunteers: a double-blind, phase I study.
Barbhaiya, RH; Gammans, RR; Greene, DS; Marathe, PH; Mayol, RF; Pittman, KA; Robinson, D; Shukla, UA, 1995)		0.29

Pharmacokinetics

ExcerptReferenceRelevance
" Cmax plasma levels of nefazodone and hydroxynefazodone were attained within 2 hours of administration of nefazodone; tmax for m-chlorophenylpiperazine was more delayed, and p-hydroxynefazodone levels were generally below the assay limit."( Nonlinear pharmacokinetics of nefazodone after escalating single and multiple oral doses.
Barbhaiya, RH; Kaul, S; Shukla, UA, 1995)		0.56
"The steady-state pharmacokinetic interaction between nefazodone and cimetidine was evaluated in a three-period crossover study consisting of three treatments of 1 week duration with a 1 week washout between treatments."( Lack of interaction between nefazodone and cimetidine: a steady state pharmacokinetic study in humans.
Barbhaiya, RH; Greene, DS; Shukla, UA, 1995)		0.29
" A single blood sample was collected on 8 different days for assessment of trough levels (Cmin) and serial samples were obtained on days 5, 9, and 22 of dosing for pharmacokinetic profiles."( Safety, tolerance, and preliminary pharmacokinetics of nefazodone after administration of single and multiple oral doses to healthy adult male volunteers: a double-blind, phase I study.
Barbhaiya, RH; Gammans, RR; Greene, DS; Marathe, PH; Mayol, RF; Pittman, KA; Robinson, D; Shukla, UA, 1995)		0.29
" Serial blood samples for pharmacokinetic analysis were collected for 48 h following each dose and plasma samples were assayed for NEF, HO-NEF and mCPP by a validated HPLC method."( Single-dose pharmacokinetics of nefazodone in healthy young and elderly subjects and in subjects with renal or hepatic impairment.
Barbhaiya, RH; Greene, DS; Shukla, UA, 1995)		0.29
" Single trough blood samples just prior to each morning dose (Cmin) and serial samples after the dose on day 8 were obtained at each dose level for pharmacokinetic analysis."( Steady-state pharmacokinetics of nefazodone in subjects with normal and impaired renal function.
Barbhaiya, RH; Brady, ME; Greene, DS; Shukla, UA, 1995)		0.29
" For the 200 mg dose group, the single dose plasma results showed no significant differences in pharmacokinetic parameters for NEF and HO-NEF in EM compared with PM subjects."( Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan.
Barbhaiya, RH; Buch, AB; Greene, DS, 1996)		0.29
"To evaluate the possible pharmacokinetic interaction between nefazodone and lithium."( Pharmacokinetic evaluation of co-administration of nefazodone and lithium in healthy subjects.
Cheuvart, B; Cosson, JP; Decourt, JP; Girault, J; Ingrand, I; Istin, B; Laroudie, C; Salazar, DE, 1999)		0.3
"Co-administration of nefazodone did not modify pharmacokinetic parameters of lithium at steady-state."( Pharmacokinetic evaluation of co-administration of nefazodone and lithium in healthy subjects.
Cheuvart, B; Cosson, JP; Decourt, JP; Girault, J; Ingrand, I; Istin, B; Laroudie, C; Salazar, DE, 1999)		0.3

Bioavailability

ExcerptReferenceRelevance
"The bioavailability of NEF, based on AUC(INF), from proximal and distal regions relative to that from oral administration was 97% and 106%, respectively."( Absorption and presystemic metabolism of nefazodone administered at different regions in the gastrointestinal tract of humans.
Barbhaiya, RH; Brennan, J; Greene, DS; Marathe, PH; Salazar, DE; Shukla, UA, 1995)		0.29

Dosage Studied

ExcerptRelevanceReference
" On repeated twice-daily dosing of nefazodone, steady-state levels of the drug and its metabolites were reached within 3 days."( Nonlinear pharmacokinetics of nefazodone after escalating single and multiple oral doses.
Barbhaiya, RH; Kaul, S; Shukla, UA, 1995)		0.29
" When nefazodone and cimetidine were co-administered for 1 week, no change in steady-state pharmacokinetic parameters for cimetidine, nefazodone or hydroxynefazodone was observed compared with each drug dosed alone."( Lack of interaction between nefazodone and cimetidine: a steady state pharmacokinetic study in humans.
Barbhaiya, RH; Greene, DS; Shukla, UA, 1995)		0.49
" Each dosage level was administered for 2 days before proceeding to the next higher dose from 5 mg or 10 mg 3 times a day to a maximum of 500 mg 3 times a day."( Safety, tolerance, and preliminary pharmacokinetics of nefazodone after administration of single and multiple oral doses to healthy adult male volunteers: a double-blind, phase I study.
Barbhaiya, RH; Gammans, RR; Greene, DS; Marathe, PH; Mayol, RF; Pittman, KA; Robinson, D; Shukla, UA, 1995)		0.29
" Serial plasma and urine samples were collected at specified time intervals after dosing on Days 1, 16, 18, 20 and 22."( Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan.
Barbhaiya, RH; Buch, AB; Greene, DS, 1996)		0.29
" was added to the lithium dosing regimen."( Pharmacokinetic evaluation of co-administration of nefazodone and lithium in healthy subjects.
Cheuvart, B; Cosson, JP; Decourt, JP; Girault, J; Ingrand, I; Istin, B; Laroudie, C; Salazar, DE, 1999)		0.3
"Since there were no clinically significant changes in the pharmacokinetics of the parent compounds or metabolites, and the combination was well tolerated, no dosage adjustments of nefazodone or lithium are necessary when they are co-administered."( Pharmacokinetic evaluation of co-administration of nefazodone and lithium in healthy subjects.
Cheuvart, B; Cosson, JP; Decourt, JP; Girault, J; Ingrand, I; Istin, B; Laroudie, C; Salazar, DE, 1999)		0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
piperazines
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's12 (80.00)18.2507
2000's3 (20.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.10

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.10 (24.57)
Research Supply Index3.09 (2.92)
Research Growth Index4.20 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.10)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials6 (40.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (60.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
1-(3-chlorophenyl)piperazine
1-(3-chlorophenyl)piperazine: supposed metabolite of TRAZODONE; RN given refers to parent cpd; structure. 1-(3-chlorophenyl)piperazine : A N-arylpiperazine that is piperazine carrying a 3-chlorophenyl substituent at position 1. It is a metabolite of the antidepressant drug trazodone.		6.63125monochlorobenzenes;
N-arylpiperazine		drug metabolite;
environmental contaminant;
serotonergic agonist;
xenobiotic
cimetidine
Cimetidine: A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.. cimetidine : A member of the class of guanidines that consists of guanidine carrying a methyl substituent at position 1, a cyano group at position 2 and a 2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl group at position 3. It is a H2-receptor antagonist that inhibits the production of acid in stomach.		3.3711aliphatic sulfide;
guanidines;
imidazoles;
nitrile		adjuvant;
analgesic;
anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor
p-chloroamphetamine
p-Chloroamphetamine: Chlorinated analog of AMPHETAMINE. Potent neurotoxin that causes release and eventually depletion of serotonin in the CNS. It is used as a research tool.		1.9910
ketoconazole
1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.		2.0110dichlorobenzene;
dioxolane;
ether;
imidazoles;
N-acylpiperazine;
N-arylpiperazine
nefazodone
nefazodone: may be useful as an opiate adjunct		7.02156aromatic ether;
monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
triazoles		alpha-adrenergic antagonist;
analgesic;
antidepressant;
serotonergic antagonist;
serotonin uptake inhibitor
quipazine
Quipazine: A pharmacologic congener of serotonin that contracts smooth muscle and has actions similar to those of tricyclic antidepressants. It has been proposed as an oxytocic.		1.9910piperazines;
pyridines
triazoles
Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.		7.021561,2,3-triazole
lithium
Lithium: An element in the alkali metals family. It has the atomic symbol Li, atomic number 3, and atomic weight [6.938; 6.997]. Salts of lithium are used in treating BIPOLAR DISORDER.		3.3811alkali metal atom
dextromethorphan
Dextromethorphan: Methyl analog of DEXTRORPHAN that shows high affinity binding to several regions of the brain, including the medullary cough center. This compound is an NMDA receptor antagonist (RECEPTORS, N-METHYL-D-ASPARTATE) and acts as a non-competitive channel blocker. It is one of the widely used ANTITUSSIVES, and is also used to study the involvement of glutamate receptors in neurotoxicity.. dextromethorphan : A 6-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthrene in which the sterocenters at positions 4a, 10 and 10a have S-configuration. It is a prodrug of dextrorphan and used as an antitussive drug for suppressing cough.		3.37116-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthreneantitussive;
environmental contaminant;
neurotoxin;
NMDA receptor antagonist;
oneirogen;
prodrug;
xenobiotic
ConditionIndicatedRelationship StrengthStudiesTrials
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		02.4220
Cirrhosis, Liver
[description not available]		02.3920
Liver Cirrhosis
Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.		02.3920
Liver Dysfunction
[description not available]		03.3711
Liver Diseases
Pathological processes of the LIVER.		03.3711
Kidney Diseases
Pathological processes of the KIDNEY or its component tissues.		02.3920